

# WHI-P180

**Catalog No: tcsc1702**



## Available Sizes

---

**Size:** 2mg

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg



## Specifications

---

**CAS No:**

211555-08-7

**Formula:**

$C_{16}H_{15}N_3O_3$

**Pathway:**

Protein Tyrosine Kinase/RTK;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK

**Target:**

VEGFR;EGFR;EGFR

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Alternative Names:**

Janex 3

**Observed Molecular Weight:**


297.31

## Product Description

WHI-P180 (Janex 3) is a multi-kinase inhibitor; inhibits **RET**, **KDR** and **EGFR** with **IC<sub>50</sub>s** of 5 nM, 66 nM and 4 μM, respectively.

IC50 & Target: IC50: 5 nM (RET), 66 nM (KDR)<sup>[1]</sup>, 4 μM (EGFR)<sup>[2]</sup>

**In Vivo:** WHI-P180 is also an active inhibitor of IgE-mediated mast cell responses. The elimination half-life of WHI-P180 in CD-1 mice (BALB/c mice) following i.v., i.p., or p.o. administration is less than 10 min. Systemic clearance of WHI-P180 is 6742 mL/h/kg in CD-1 mice and 8188 mL/h/kg in BALB/c mice. Notably, WHI-P180, when administered in two consecutive nontoxic i.p. bolus doses of 25 mg/kg, inhibits IgE/antigen-induced vascular hyperpermeability in a well-characterized murine model of passive cutaneous anaphylaxis<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!